Given that mutant SOD1 instability appears to correlate with ALS disease severity in humans [7], we propose that boosting levels of functional and natively folded SOD1 with anti-SOD1 nanobodies is a viable therapeutic direction for treating ALS. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.